<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989699</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-TKI-2020-101</org_study_id>
    <nct_id>NCT04989699</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects&#xD;
      with Neovascular Age-Related Macular Degeneration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, double masked, randomized, parallel-group study to evaluate the safety,&#xD;
      tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular&#xD;
      Age-Related Macular Degeneration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) change</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA changes</measure>
    <time_frame>Baseline through 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central subfield thickness changes</measure>
    <time_frame>Baseline through 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Therapy</measure>
    <time_frame>Baseline through 36 weeks</time_frame>
    <description>Proportion of subjects receiving rescue therapy, mean time to rescue, mean number of rescue injections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>OTX-TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI/Sham</intervention_name>
    <description>OTX-TKI is one dose so subsequent visits will be sham to maintain the mask</description>
    <arm_group_label>OTX-TKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept/Sham</intervention_name>
    <description>Aflibercept administered every 8 weeks</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis, within 3 years of screening, of previously treated subfoveal&#xD;
             neovascularization (SFNV) secondary to nAMD with leakage involving the fovea,&#xD;
             previously treated with documented evidence of an initially favorable clinical&#xD;
             response to anti-VEGF therapy (i.e. aflibercept, ranibizumab, brolucizumab, or&#xD;
             bevacizumab).&#xD;
&#xD;
          -  The macular appearance on OCT is considered to be free of excess intraretinal and/or&#xD;
             subretinal fluid as judged by the investigator.&#xD;
&#xD;
          -  Must have received at least 3 anti-VEGF injections in the past year.&#xD;
&#xD;
          -  Have received the most recent anti-VEGF injection within the past 1-4 weeks prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  BCVA ETDRS score between 24 and 83 letters (~20/25 to ~20/320 Snellen equivalent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have evidence of a scar, fibrosis or atrophy of &gt;50% of the total lesion in the study&#xD;
             eye&#xD;
&#xD;
          -  Have presence of a disease other than choroidal neovascular membrane (CNVM) due to AMD&#xD;
             in the study eye that could affect vision or safety assessments&#xD;
&#xD;
          -  Have monocular vision (fellow eye Snellen BCVA is 20/200 or worse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>1-781-357-4000</phone>
    <email>clinicalaffairs@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

